'Moonshot' at liver cell therapy biotech Ambys Medicines comes to an end
Ambys Medicines, backed by Third Rock Ventures and a partner to Takeda, closed its doors in recent months without a big public disclosure, but multiple employees flashed signals on a networking site.
The South San Francisco biotech planned to make a hepatocyte replacement cell therapy for liver disease, but per one former employee, Ambys “could not convince investors to bring this transformative therapy to patients at this time,” according to a LinkedIn post. A former executive wrote on the job networking platform that the shuttering was due to “a set of unfortunate circumstances.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.